The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Open accessAbstract
Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.Methods In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.Findings Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.Interpretation Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Initial results demonstrated a 31% objective response rate and 69% demonstrated at least 12 weeks of stable disease [78].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [78]
In the citing paper
“The Checkmate-142 phase II study demonstrated the effectiveness of nivolumab in previously treated MSI-H mCRC patients [84].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Upon examining the subgroup analysis of this study, it was observed that patients without RAS or BRAF mutations achieved a 41% objective response rate with nivolumab. In comparison, the rate was 27% in RAS mutant patients.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53,54,55,56].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Nivolumab, an anti-PD1 monoclonal antibody (moAb), has been utilized since 1 August 2017, for MSI-H/dMMR mCRC, as evidenced by the CheckMate 142 study [54].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“The CHECKMATE 142 study reported that Nivolumab could provide a durable response in patients with dMMR/MSI-H metastatic colorectal cancer, proposing Nivolumab as a new treatment option in these patients [117].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [117]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cited by
Sorted by citations
Items 201–300 of 1,005
Li, J., Deng, Y., Zhang, W., Zhou, A., Guo, W., Yang, J., Yuan, Y., Zhu, L., Qin, S., Xiang, S., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01095-1 · Cited by 151
Predictive biomarkers of colon cancer immunotherapy: Present and future
Hou, W., Cheng, Y., & Zhu, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032314 · Cited by 151
Chen, G., Jin, Y., Guan, W., Zhang, R., Xiao, W., Cai, P., Liu, M., Lin, J., Wang, F., Li, C., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00439-3 · Cited by 157
Mismatch repair deficiency: The what, how and why it is important
Olave, M. C., & Graham, R. P. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23015 · Cited by 158
Current status of immunotherapy in metastatic colorectal cancer
Wróbel, P., & Ahmed, S. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3202-8 · Cited by 144
Therapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 151
Immune regulation of metastasis: mechanistic insights and therapeutic opportunities
Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036236 · Cited by 145
Yoshino, T., Pentheroudakis, G., Mishima, S., Overman, M. J., Yeh, K., Baba, E., Naito, Y., Calvo, F. M., Saxena, A. K., Chen, L.-T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.299 · Cited by 142
Self-citationLimagne, E., Thibaudin, M., Nuttin, L., Spill, A., Dérangère, V., Fumet, J.-D., Amellal, N., Peranzoni, E., Cattan, V., & Ghiringhelli, F. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0228 · Cited by 146
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
Ferretti, S., Hamon, J., de Kanter, R., Scheufler, C., Andraos, R., Barbé, S., Bechter, E., Blank, J., Bordas, V., Dammassa, E., et al. (2024) · Nature · doi:10.1038/s41586-024-07350-y · Cited by 152
Recent advances in Lynch syndrome
Biller, L. H., Syngal, S., & Yurgelun, M. B. B. (2019) · Familial Cancer · doi:10.1007/s10689-018-00117-1 · Cited by 151
André, T., Berton, D., Curigliano, G., Sabatier, R., Tinker, A. V., Oaknin, A., Ellard, S. L., de Braud, F., Arkenau, H., Trigo, J. M., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.41165 · Cited by 149
Self-citationOzato, Y., Kojima, Y., Kobayashi, Y., Hisamatsu, Y., Toshima, T., Yonemura, Y., Masuda, T., Kagawa, K., Goto, Y., Utou, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2022.111929 · Cited by 144
Precision immunoprofiling by image analysis and artificial intelligence
Koelzer, V. H., Sirinukunwattana, K., Rittscher, J., & Mertz, K. D. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2485-z · Cited by 148
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Cui, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.562315 · Cited by 156
Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention
Yurgelun, M. B. B., & Hampel, H. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_208341 · Cited by 141
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 139
Self-citationMorano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02583 · Cited by 134
Self-citationNeoadjuvant immunotherapy in primary and metastatic colorectal cancer
Kanani, A. N., Veen, T., & Søreide, K. (2021) · British journal of surgery · doi:10.1093/bjs/znab342 · Cited by 135
The role of neoantigen in immune checkpoint blockade therapy
Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0120-y · Cited by 132
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Shen, X., Zhang, L., Li, J., Li, Y., Wang, Y., & Xu, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01337 · Cited by 133
Allouchery, M., Lombard, T., Martin, M., Rouby, F., Sassier, M., Bertin, C., Atzenhoffer, M., Miremont‐Salamé, G., Pérault‐Pochat, M., & Puyade, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001622 · Cited by 133
Xie, L., Wang, G., Sang, W., Li, J., Zhang, Z., Li, W., Yan, J., Zhao, Q., & Dai, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120638 · Cited by 133
The landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 140
Mettu, N. B., Ou, F., Zemla, T., Halfdanarson, T. R., Lenz, H., Breakstone, R., Boland, P. M., Crysler, O., Wu, C. S.-Y., Nixon, A. B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.49040 · Cited by 135
Self-citationRecent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 140
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
Overman, M. J., Ernstoff, M. S., & Morse, M. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200821 · Cited by 131
Self-citationVariant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 131
Fucà, G., Cohen, R., Lonardi, S., Shitara, K., Elez, M. E., Fakih, M., Chao, J., Klempner, S. J., Emmett, M., Jayachandran, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004001 · Cited by 129
Self-citationThe Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Germano, G., Amirouchene-Angelozzi, N., Rospo, G., & Bardelli, A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0150 · Cited by 130
Current Targeted Therapy for Metastatic Colorectal Cancer
Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 138
PD‐1/PD‐L1‐dependent immune response in colorectal cancer
Payandeh, Z., Khalili, S., Somi, M. H., Mard‐Soltani, M., Baghbanzadeh, A., Hajiasgharzadeh, K., Samadi, N., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29494 · Cited by 129
Current advancements and future perspectives of immunotherapy in colorectal cancer research
Kishore, C., & Bhadra, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173819 · Cited by 126
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 132
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 143
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Roviello, G., D’Angelo, A., Petrioli, R., Roviello, F., Cianchi, F., Nobili, S., Mini, E., & Lavacchi, D. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100795 · Cited by 129
Mpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 130
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
Morse, M. A., Höchster, H. S., & Benson, A. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0176 · Cited by 123
Self-citationPetrelli, F., Ghidini, M., Ghidini, A., & Tomasello, G. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1046 · Cited by 123
Personalized immunotherapy in cancer precision medicine
Kiyotani, K., Toyoshima, Y., & Nakamura, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0032 · Cited by 136
Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122
The impact of microsatellite stability status in colorectal cancer
Gupta, R., Sinha, S., & Paul, R. N. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.06.010 · Cited by 125
de Salins, A. G. D., Tachon, G., Cohen, R., Karayan, L., Junca, A., Frouin, É., Godet, J., Evrard, C., Randrian, V., Duval, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100120 · Cited by 123
Self-citationRecent developments in immunotherapy for gastrointestinal tract cancers
Chong, X., Madeti, Y., Cai, J., Li, W., Cong, L., Lu, J., Mo, L., Liu, H., He, S., Yu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01578-x · Cited by 132
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 122
Gonzalez-Exposito, R., Semiannikova, M., Griffiths, B. L., Khan, K. H., Barber, L. J., Woolston, A., Spain, G., von Loga, K., Challoner, B. R., Patel, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0575-3 · Cited by 121
Optimizing immunotherapy for colorectal cancer
Ganesh, K. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00569-4 · Cited by 120
Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112
Self-citationOncolytic viruses: overcoming translational challenges
Martínez‐Quintanilla, J., Seah, I. Y. J., Chua, M. M. J., & Shah, K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122287 · Cited by 122
Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer
Temraz, S. N., Nassar, F. J., Nasr, R., Charafeddine, M., Mukherji, D., & Shamseddine, A. I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174155 · Cited by 125
Heinzerling, L., Toni, E. D., Schett, G. A., Hundorfean, G., & Zimmer, L. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0119 · Cited by 123
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 118
Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
Cohen, R., Rousseau, B., Vidal, J., Colle, R., Diaz, L. A., & André, T. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00690-0 · Cited by 119
Self-citationCorti, F., Lonardi, S., Intini, R., Salati, M., Fenocchio, E., Belli, C., Borelli, B., Brambilla, M., Prete, A. A., Quarà, V., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.043 · Cited by 116
Self-citationWang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131
Zou, F., Tan, J., Liu, T., Liu, B., Tang, Y., Zhang, H., & Li, J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.021 · Cited by 120
Ashizawa, M., Okayama, H., Ishigame, T., Min, A. K. T., Saito, K., Ujiie, D., Murakami, Y., Kikuchi, T., Nakayama, Y., Noda, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0831 · Cited by 115
Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives
Taı̈eb, J., André, T., & Auclin, É. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.02.002 · Cited by 115
Self-citationLi, Y., He, M., Zhou, Y., Yang, C., Wei, S., Bian, X., Christopher, O., & Xie, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00139 · Cited by 119
Adjuvant Chemotherapy for Stage III Colon Cancer
Taı̈eb, J., & Gallois, C. (2020) · Cancers · doi:10.3390/cancers12092679 · Cited by 121
The complementarity of DDR, nucleic acids and anti-tumour immunity
Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 117
Wu, D., Li, Y., Xu, P., Fang, Q., Cao, F., Lin, H., Li, Y., Su, Y., Lu, L., Chen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46444-z · Cited by 124
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 116
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 113
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
Reynolds, K. L., Thomas, M. F., & Dougan, M. L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0174 · Cited by 112
Middha, S., Yaeger, R. D., Shia, J., Stadler, Z. K., King, S., Guercio, S., Paroder, V., Bates, . D. B., Rana, S., Diaz, L. A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00321 · Cited by 116
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Bianchi, A. S., Tomasello, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01254 · Cited by 116
Self-citationTakada, K., Sugita, S., Murase, K., Kikuchi, T., Oomori, G., Ito, R., Hayasaka, N., Miyanishi, K., Iyama, S., Ikeda, H., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13215 · Cited by 113
Loupakis, F., Depetris, I., Biason, P., Intini, R., Prete, A. A., Leone, F., Lombardi, P., Filippi, R., Spallanzani, A., Cascinu, S., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0611 · Cited by 117
Self-citationImmunotherapy in Colorectal Cancer: Current and Future Strategies
Ooki, A., Shinozaki, E., & Yamaguchi, K. (2021) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2020-064 · Cited by 111
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
Michel, M. S., Kaps, L., Maderer, A., Galle, P. R., & Moehler, M. H. (2021) · Cancers · doi:10.3390/cancers13102296 · Cited by 115
Liu, R., Lu, Z., Gu, J., Liu, J., Huang, E., Liu, X., Wang, L., Yang, J., Deng, Y., Qian, J., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.09.045 · Cited by 113
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1569 · Cited by 116
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
Pietrantonio, F., Nicolantonio, F. D., Schrock, A. B., Lee, J., Morano, F., Fucà, G., Nikolinakos, P. G., Drilon, A. E. D. C., Hechtman, J. F., Christiansen, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy090 · Cited by 108
Monjazeb, A. M., Giobbie‐Hurder, A., Lako, A., Thrash, E. M., Brennick, R. C., Kao, K. Z., Manuszak, C., Gentzler, R. D., Tesfaye, A. A., Jabbour, S. K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4632 · Cited by 112
Novel targeting approaches and signaling pathways of colorectal cancer: An insight
Tiwari, A., Saraf, S., Verma, A., Panda, P. K., & Jain, S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i39.4428 · Cited by 109
Hechtman, J. F., Rana, S., Middha, S., Stadler, Z. K., Latham, A. J., Benayed, R., Soslow, R. A., Ladanyi, M., Yaeger, R. D., Zehir, A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0414-6 · Cited by 107
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 113
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
van de Donk, P. P., de Ruijter, L. K., Hooge, M. N. L., Brouwers, A. H., van der Wekken, A. J., Oosting, S. F., Fehrmann, R. S. N., de Groot, D. J. A., & de Vries, E. G. E. (2020) · Theranostics · doi:10.7150/thno.38339 · Cited by 109
Immune Activation in Mismatch Repair–Deficient Carcinogenesis: More Than Just Mutational Rate
Willis, J. A., Reyes-Uribe, L., Chang, K., Lipkin, S. M., & Vilar, E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0856 · Cited by 104
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 106
Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
Mulet-Margalef, N., Linares, J., Badia-Ramentol, J., Jimeno, M., Sanz, C., Mozo, J. L. M., & Calon, A. (2023) · Cancers · doi:10.3390/cancers15041022 · Cited by 112
Eng, L., Sutradhar, R., Niu, Y., Liu, N., Liu, Y., Kaliwal, Y., Powis, M., Liu, G., Peppercorn, J. M., Bedard, P. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00074 · Cited by 106
Chen, J., Sun, H.-W., Yang, Y., Chen, H., Yu, X.-J., Wu, W., Xu, Y.-T., Jin, L.-L., Wu, X., Xu, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00377-3 · Cited by 105
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 103
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Wienand, K., Kamburov, A., Griffin, G. K., Chen, P.-H., Lako, A., Redd, R. A., et al. (2019) · Blood · doi:10.1182/blood.2019002067 · Cited by 108
Memmott, R. M., Wolfe, A. R., Carbone, D. P., & Williams, T. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.017 · Cited by 105
Homologous Recombination Repair Deficiency: An Overview for Pathologists
Doig, K., FELLOWES, A. P., & Fox, S. B. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100049 · Cited by 103
Informing immunotherapy with multi-omics driven machine learning
Li, Y., Xin, W., Fang, D., & Luo, Y. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01043-6 · Cited by 120
A machine learning approach for somatic mutation discovery
Wood, D. E., White, J. R., Georgiadis, A. P., Emburgh, B. V., Parpart-Li, S. T., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7939 · Cited by 101
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S., & Bekaii‐Saab, T. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8196 · Cited by 106
The Role of Immunotherapy in Pancreatic Cancer
Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 106
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 107
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
Ambrosini, M., Rousseau, B., Manca, P., Artz, O., Marabelle, A., André, T., Maddalena, G., Mazzoli, G., Intini, R., Cohen, R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.009 · Cited by 118
Self-citationAlteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Wu, H., Chen, Y., Wang, Z.-X., Zhao, Q., He, M.-M., Wang, Y.-N., Wang, F., & Xu, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0737-3 · Cited by 100
Immune scores in colorectal cancer: Where are we?
Malka, D., Lièvre, A., André, T., Taı̈eb, J., Ducreux, M. P., & Bibeau, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.024 · Cited by 101
Self-citationHamada, T., Nowak, J. A., Milner, D. A., Song, M., & Ogino, S. (2019) · The Journal of Pathology · doi:10.1002/path.5236 · Cited by 100
Huyghe, N. D., Baldin, P., & den Eynde, M. V. (2019) · Gastroenterology report · doi:10.1093/gastro/goz061 · Cited by 106
Le, D. T., Diaz, L. A., Kim, T. W., Cutsem, E. V., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B. H., Kavan, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.016 · Cited by 100
Self-citation
Metadata
- Authors
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V., Cao, Z. A., Ledeine, J.-M., Maglinte, G. A., Kopetz, S., & André, T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Trials Ireland (IE)
- Allina Health (US)
- Istituto Oncologico Veneto (IT)
- USC Norris Comprehensive Cancer Center (US)
- Duke Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Belgium) (BE)
- Sorbonne Université (FR)
- Corresponding author
- Overman, Michael J
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 18
- Issue
- 9
- Pages
- 1182-1191
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC6207072
- OpenAlex
- W2739132742
- Cited by
- 2,836
- References
- 37
- Citations by year
- 2026: 185 · 2025: 242 · 2024: 302 · 2023: 382 · 2022: 377 · 2021: 438 · 2020: 361 · 2019: 288 · 2018: 223 · 2017: 31
- FWCI
- 108.88
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-01)
- Open access
- green
- europepmc.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (P30CA016672)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- nivolumab, metastatic colorectal cancer, mismatch repair deficiency, microsatellite instability-high, PD-1 inhibitors, immune checkpoint blockade, objective response rate, disease control rate, progression-free survival, overall survival, treatment toxicity, first-line therapy, second-line therapy, third-line therapy, neoantigens, tumor-infiltrating lymphocytes
- MeSH terms
- Nivolumab, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Microsatellite Instability, DNA Mismatch Repair, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
